Cargando…

Evaluation of a methylation classifier for predicting pre-cancer lesion among women with abnormal results between HPV16/18 and cytology

BACKGROUND: Although HPV testing and cytology detection are successful for cervical screening in China, additional procedures are urgently required to avoid misdiagnosis and overtreatment. In this multicenter study, we collected cervical samples during screening in clinics. A total of 588 women with...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Yuan-Yuan, Zhou, Guan-Nan, Wang, Qing, Ding, Jing-Xin, Hua, Ke-Qin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175486/
https://www.ncbi.nlm.nih.gov/pubmed/32317020
http://dx.doi.org/10.1186/s13148-020-00849-x
_version_ 1783524840509014016
author Gu, Yuan-Yuan
Zhou, Guan-Nan
Wang, Qing
Ding, Jing-Xin
Hua, Ke-Qin
author_facet Gu, Yuan-Yuan
Zhou, Guan-Nan
Wang, Qing
Ding, Jing-Xin
Hua, Ke-Qin
author_sort Gu, Yuan-Yuan
collection PubMed
description BACKGROUND: Although HPV testing and cytology detection are successful for cervical screening in China, additional procedures are urgently required to avoid misdiagnosis and overtreatment. In this multicenter study, we collected cervical samples during screening in clinics. A total of 588 women with HPV16/18+ and/or cytology result ≥HSIL+ (high-grade squamous intraepithelial lesion or worse) were referred to colposcopy for pathological diagnosis. Methylation of S5 was quantified by pyrosequencing. RESULTS: The S5 classifier separates women with ≥HSIL+ from <HSIL with a high area under the curve (AUC) of 0.86 (95% CI 0.840–0.910). The cutoff of 2.85 was conducted in our study. Remarkably, all cancer cases (n = 67) were detected by S5. The sensitivity of S5 for “≥HSIL+” was 89.1% (95% CI 86.2–92.4%), and the specificity was 76.6% (95% CI 72.2–78.9%). S5 could reduce unnecessary colposcopy referrals by 74% (95% CI 71.3–78.1%) with virtually no loss of sensitivity for HSIL+, and the follow-up data support the utility of the S5 classifier. CONCLUSION: The S5 classifier with high sensitivity and specificity provided increasing diagnostic information for women with HPV16/18+ and/or cytology results and could reduce the numerous unnecessary colposcopy referrals and avoid overtreatment.
format Online
Article
Text
id pubmed-7175486
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-71754862020-04-24 Evaluation of a methylation classifier for predicting pre-cancer lesion among women with abnormal results between HPV16/18 and cytology Gu, Yuan-Yuan Zhou, Guan-Nan Wang, Qing Ding, Jing-Xin Hua, Ke-Qin Clin Epigenetics Research BACKGROUND: Although HPV testing and cytology detection are successful for cervical screening in China, additional procedures are urgently required to avoid misdiagnosis and overtreatment. In this multicenter study, we collected cervical samples during screening in clinics. A total of 588 women with HPV16/18+ and/or cytology result ≥HSIL+ (high-grade squamous intraepithelial lesion or worse) were referred to colposcopy for pathological diagnosis. Methylation of S5 was quantified by pyrosequencing. RESULTS: The S5 classifier separates women with ≥HSIL+ from <HSIL with a high area under the curve (AUC) of 0.86 (95% CI 0.840–0.910). The cutoff of 2.85 was conducted in our study. Remarkably, all cancer cases (n = 67) were detected by S5. The sensitivity of S5 for “≥HSIL+” was 89.1% (95% CI 86.2–92.4%), and the specificity was 76.6% (95% CI 72.2–78.9%). S5 could reduce unnecessary colposcopy referrals by 74% (95% CI 71.3–78.1%) with virtually no loss of sensitivity for HSIL+, and the follow-up data support the utility of the S5 classifier. CONCLUSION: The S5 classifier with high sensitivity and specificity provided increasing diagnostic information for women with HPV16/18+ and/or cytology results and could reduce the numerous unnecessary colposcopy referrals and avoid overtreatment. BioMed Central 2020-04-21 /pmc/articles/PMC7175486/ /pubmed/32317020 http://dx.doi.org/10.1186/s13148-020-00849-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Gu, Yuan-Yuan
Zhou, Guan-Nan
Wang, Qing
Ding, Jing-Xin
Hua, Ke-Qin
Evaluation of a methylation classifier for predicting pre-cancer lesion among women with abnormal results between HPV16/18 and cytology
title Evaluation of a methylation classifier for predicting pre-cancer lesion among women with abnormal results between HPV16/18 and cytology
title_full Evaluation of a methylation classifier for predicting pre-cancer lesion among women with abnormal results between HPV16/18 and cytology
title_fullStr Evaluation of a methylation classifier for predicting pre-cancer lesion among women with abnormal results between HPV16/18 and cytology
title_full_unstemmed Evaluation of a methylation classifier for predicting pre-cancer lesion among women with abnormal results between HPV16/18 and cytology
title_short Evaluation of a methylation classifier for predicting pre-cancer lesion among women with abnormal results between HPV16/18 and cytology
title_sort evaluation of a methylation classifier for predicting pre-cancer lesion among women with abnormal results between hpv16/18 and cytology
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175486/
https://www.ncbi.nlm.nih.gov/pubmed/32317020
http://dx.doi.org/10.1186/s13148-020-00849-x
work_keys_str_mv AT guyuanyuan evaluationofamethylationclassifierforpredictingprecancerlesionamongwomenwithabnormalresultsbetweenhpv1618andcytology
AT zhouguannan evaluationofamethylationclassifierforpredictingprecancerlesionamongwomenwithabnormalresultsbetweenhpv1618andcytology
AT wangqing evaluationofamethylationclassifierforpredictingprecancerlesionamongwomenwithabnormalresultsbetweenhpv1618andcytology
AT dingjingxin evaluationofamethylationclassifierforpredictingprecancerlesionamongwomenwithabnormalresultsbetweenhpv1618andcytology
AT huakeqin evaluationofamethylationclassifierforpredictingprecancerlesionamongwomenwithabnormalresultsbetweenhpv1618andcytology